Clinical Trial Update: Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating icotinib with radiation therapy for non-small cell lung cancer with brain metastases and EGFR mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-Small Cell Lung Cancer, Brain Metastases | Phase 2 | Status: UNKNOWN